Epidermal Growth Factor Receptor and K-RAS status in two cohorts of squamous cell carcinomas

[1]  R. Hofheinz,et al.  Cetuximab-Based Treatment of Metastatic Anal Cancer: Correlation of Response with KRAS Mutational Status , 2009, Oncology.

[2]  Xavier Duval,et al.  Growth factor receptor expression in anal squamous lesions: modifications associated with oncogenic human papillomavirus and human immunodeficiency virus. , 2009, Human pathology.

[3]  M. Zampino,et al.  K-ras status in squamous cell anal carcinoma (SCC): it’s time for target-oriented treatment? , 2009, Cancer Chemotherapy and Pharmacology.

[4]  A. Egloff,et al.  Improving Response Rates to EGFR-Targeted Therapies for Head and Neck Squamous Cell Carcinoma: Candidate Predictive Biomarkers and Combination Treatment with Src Inhibitors , 2009, Journal of oncology.

[5]  A. Jemal,et al.  Cancer Statistics, 2009 , 2009, CA: a cancer journal for clinicians.

[6]  A. Iafrate,et al.  Decreased survival in EGFR gene amplified vulvar carcinoma. , 2008, Gynecologic oncology.

[7]  C. Bokemeyer,et al.  Platinum-based chemotherapy plus cetuximab in head and neck cancer. , 2008, The New England journal of medicine.

[8]  R. Grenman,et al.  Expression and mutation analysis of epidermal growth factor receptor in head and neck squamous cell carcinoma , 2008, Cancer science.

[9]  H. Zwierzina,et al.  Identification of the rare EGFR mutation p.G796S as somatic and germline mutation in white patients with squamous cell carcinoma of the head and neck , 2008, Head & neck.

[10]  K. Nakachi,et al.  Exon 19 of EGFR mutation in relation to the CA‐repeat polymorphism in intron 1 , 2008, Cancer science.

[11]  Daniel J. Freeman,et al.  Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  G. Tortora,et al.  EGFR antagonists in cancer treatment. , 2008, The New England journal of medicine.

[13]  E. Van Cutsem,et al.  KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  M. Páez de la Cadena,et al.  Absence of Activating Mutations in the EGFR Kinase Domain in Spanish Head and Neck Cancer Patients , 2007, Tumor Biology.

[15]  Diane D. Liu,et al.  Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  Manuel Hidalgo,et al.  Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  Marc Peeters,et al.  Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  H. Kang,et al.  EGFR mutations and human papillomavirus in squamous cell carcinoma of tongue and tonsil. , 2007, European journal of cancer.

[19]  Christine H Chung,et al.  Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  John Mendelsohn,et al.  Epidermal growth factor receptor targeting in cancer. , 2006, Seminars in oncology.

[21]  Hanlin L. Wang,et al.  Expression of epidermal growth factor receptor in squamous cell carcinomas of the anal canal is independent of gene amplification , 2006, Modern Pathology.

[22]  A. Lièvre,et al.  KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. , 2006, Cancer research.

[23]  M. Ladanyi,et al.  Clinical Course of Patients with Non–Small Cell Lung Cancer and Epidermal Growth Factor Receptor Exon 19 and Exon 21 Mutations Treated with Gefitinib or Erlotinib , 2006, Clinical Cancer Research.

[24]  M. Moore,et al.  Epidermal growth factor receptor expression in anal canal carcinoma. , 2005, American journal of clinical pathology.

[25]  H. Lane,et al.  ERBB Receptors and Cancer: The Complexity of Targeted Inhibitors , 2005, Nature Reviews Cancer.

[26]  Elisa Rossi,et al.  Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. , 2005, Journal of the National Cancer Institute.

[27]  Suk Woo Nam,et al.  Somatic Mutations of EGFR Gene in Squamous Cell Carcinoma of the Head and Neck , 2005, Clinical Cancer Research.

[28]  R. Wilson,et al.  EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[29]  Armando Santoro,et al.  Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. , 2004, The New England journal of medicine.

[30]  P. Porter,et al.  Human papillomavirus, smoking, and sexual practices in the etiology of anal cancer , 2004, Cancer.

[31]  S. Störkel,et al.  Immunohistochemical Detection of EGFR in Paraffin-embedded Tumor Tissues , 2004, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[32]  S. Gabriel,et al.  EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.

[33]  Patricia L. Harris,et al.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.

[34]  Neal J Meropol,et al.  Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  I. Sobhani,et al.  Prevalence of high-grade dysplasia and cancer in the anal canal in human papillomavirus-infected individuals. , 2001, Gastroenterology.

[36]  T. Gilmer,et al.  ras Mutations and expression in head and neck squamous cell carcinomas , 1994, The Laryngoscope.

[37]  S. Hirohashi,et al.  Detection of DNA aberrations in human cancers by single-strand conformation polymorphism analysis of polymerase chain reaction products. , 1991, The Tohoku journal of experimental medicine.

[38]  R. Katakura,et al.  Detection of p53 gene mutations in human brain tumors by single-strand conformation polymorphism analysis of polymerase chain reaction products. , 1991, Oncogene.

[39]  N. Shepherd,et al.  Ki‐ras oncogene mutations in non‐HPV‐associated anal carcinoma , 1990, The Journal of pathology.

[40]  F.A.M. Bordonaba,et al.  Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer , 2009 .

[41]  Alona Muzikansky,et al.  Response to treatment and survival of patients with non-small cell lung cancer undergoing somatic EGFR mutation testing. , 2007, The oncologist.

[42]  H. Zwierzina,et al.  Low incidence of mutations in EGFR kinase domain in Caucasian patients with head and neck squamous cell carcinoma. , 2006, European journal of cancer.

[43]  J. Majumder,et al.  ras gene mutations in oral cancer in eastern India. , 2000, Oral oncology.

[44]  S. Taylor.  Head and neck cancer. , 1991, Cancer chemotherapy and biological response modifiers.

[45]  T. Sekiya,et al.  Detection of ras gene mutations in human lung cancers by single-strand conformation polymorphism analysis of polymerase chain reaction products. , 1990, Oncogene.

[46]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.